Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Boston Scientific Corporation    BSX

BOSTON SCIENTIFIC CORPORATION (BSX)
My previous session
Most popular
  Report  
Real-time Quote. Real-time Cboe BZX - 10/15 05:20:46 pm
36.585 USD   -1.09%
10/11GLOBAL CONNECTE : Healthcare Analytics is Projected to Register the ..
AQ
10/02BOSTON SCIENTIF : Report
CO
10/01BOSTON SCIENTIF : Competition Seeks Innovative Digital Health Concep..
PU
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/09/2018 10/10/2018 10/11/2018 10/12/2018 10/15/2018 Date
37.41(c) 36.11(c) 36(c) 36.99(c) 36.6 Last
6 492 149 12 220 714 11 330 799 8 744 278 1 195 176 Volume
+0.29% -3.48% -0.30% +2.75% -1.05% Change
More quotes
Financials (USD)
Sales 2018 9 852 M
EBIT 2018 2 406 M
Net income 2018 1 389 M
Debt 2018 4 614 M
Yield 2018 -
Sales 2019 10 564 M
EBIT 2019 2 718 M
Net income 2019 1 668 M
Debt 2019 3 742 M
Yield 2019 -
P/E ratio 2018 35,74
P/E ratio 2019 31,73
EV / Sales2018 5,66x
EV / Sales2019 5,20x
Capitalization 51 154 M
More Financials
Company
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties.It operates through the following segments: Cardiovascular, Rhythm Management, and MedSurg.The Cardiovascular segment comprises of technologies or... 
More about the company
Surperformance© ratings of Boston Scientific Corporat
Trading Rating : Investor Rating :
More Ratings
Latest news on BOSTON SCIENTIFIC CORPORAT
10/11GLOBAL CONNECTED HEALTH & WELLNESS D : Healthcare Analytics is Projected to Regi..
AQ
10/02BOSTON SCIENTIFIC CORPORATION : Report
CO
10/01BOSTON SCIENTIFIC : Competition Seeks Innovative Digital Health Concepts
PU
10/01Stryker Buys HyperBranch Medical Technology for $220 Million
DJ
10/01BOSTON SCIENTIFIC : Announces Conference Call Discussing Third Quarter 2018 Fina..
PR
10/01BOSTON SCIENTIFIC CORPORATION : Report
CO
09/24BOSTON SCIENTIFIC : Receives U.S. FDA Approval for the Eluvia™ Drug-Elutin..
PR
09/24BOSTON SCIENTIFIC CORPORATION : Report
CO
09/22BOSTON SCIENTIFIC : Eluvia Drug-Eluting Stent Demonstrates Superior Results In I..
PR
09/21BOSTON SCIENTIFIC : Launches LithoVue Empower™ Retrieval Deployment Device
PR
More news
Sector news : Advanced Medical Equipment & Technology - NEC
10/06THERMO FISHER SCIENTIFIC : Electron CEO Dived Into Economics
DJ
10/02European shares retreat as Italy, Brexit fears weigh
RE
10/02For First Time, GE Turns to an Outsider -- WSJ
DJ
10/02GE Ousts John Flannery as CEO After Missed Targets--9th Update
DJ
10/02General Electric replaces CEO with outsider; shares soar
RE
More sector news : Advanced Medical Equipment & Technology - NEC
MarketScreener Strategies on BOSTON SCIENTIFIC CORPORAT 
BOSTON SCIENTIFIC CORPORATION - 2012
All technical elements to short
SELL
More Strategies
Latest Tweets
03:50aIt's A Stock Market Correction; Here's What To Do
2
10/12$BSX Boston Scientific trading into key price support. Sitting at 50 day ..
7
10/10Ureteral Stents Market – Regional Insights And Major Key Players Like Applied.. 
10/09Boston Scientific $BSX PT Raised to $43 at Citi  
10/06A high school cancer scare drove Surbhi Sarna to found a medical device compa..
5
More tweets
Qtime:114
News from SeekingAlpha
10/08Medical device makers in the red 
09/28Jefferies bullish on Boston Scientific, sees 15% upside 
09/26RA MEDICAL SYSTEMS IPO : Expensive At 30x Sales 
09/24Cardiac device makers in the green on positive data at industry conference 
09/24FDA OKs Boston Scientific's Eluvia DES; shares up 1% premarket 
Chart BOSTON SCIENTIFIC CORPORATION
Duration : Period :
Boston Scientific Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BOSTON SCIENTIFIC CORPORAT
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Average target price 40,5 $
Spread / Average Target 9,5%
EPS Revisions
Managers
NameTitle
Michael F. Mahoney Chairman, President & Chief Executive Officer
John Bradley Sorenson Senior Vice President-Manufacturing & Supply Chain
Edward Mackey Executive Vice President-Operations
Daniel J. Brennan Chief Financial Officer & Executive Vice President
Ian T. Meredith Global Chief Medical Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
BOSTON SCIENTIFIC CORPORATION49.21%49 785
THERMO FISHER SCIENTIFIC21.87%91 068
DANAHER CORPORATION11.38%70 864
INTUITIVE SURGICAL45.78%57 809
ILLUMINA47.23%45 195
ROYAL PHILIPS11.60%38 282